Articles
31 December 2025
Vol. 3 No. 4 (2025)
Effect of metformin and empagliflozin on myocardial function in insulin-resistant patients with heart failure: rationale and design of the METRIS-HF-DZHK18 Trial
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
8
Views
4
Downloads
Authors
Impaired energy metabolism contributed to clinical severity, disease progression and to outcome in heart failure (HF). Insulin sensitivity (IS) is a key metabolic factor in the control of energy substrate utilisation and energy efficiency in cardiac and skeletal muscle. Impaired IS, or insulin resistance, is a common finding in HF and has been shown to predict morbidity and mortality in patients with heart failure with reduced and mildly reduced ejection fraction (HFrEF, HFmrEF). Despite its pathophysiologic relevance, IS has not been explored as a therapeutic target in HF. The objective of the METRIS-HF trial is to evaluate the effect of the insulin sensitizer metformin on top of standard care on myocardial contractility and functional capacity in insulin-resistant patients with HFrEF and HFmrEF in comparison to empagliflozin and placebo. METRIS-HF is an investigator initiated, multicentre, randomized, double-blind, placebo-controlled, double-dummy trial to enrol HF patients with reduced ejection fraction and insulin resistance into three parallel treatment arms in a 1:1:1 ratio to receive metformin 2x1000 daily), empagliflozin (1x10 mg/day), or double placebo, on top of standard heart failure therapy. The intervention lasts 24 weeks, followed by a 52-week follow-up period. The primary endpoint is the change in left ventricular global longitudinal strain (GLS) at 24 weeks. Key secondary endpoints include measurements of functional and symptomatic status such as 6-minute walking distance, NHYA functional class, patient global assessment (PGA), and Quality of life (EQ5D). Exploratory endpoints include metabolic, inflammatory, functional, and imaging-based biomarkers. Safety is assessed by adverse and serious adverse events throughout the trial. The METRIS-HF trial will investigate the effect of metabolic treatments to improve insulin sensitivity in patients with HFrEF and HFmrEF to provide mechanistic insights into efficacy of metabolic interventions in heart failure.
Altmetrics
Downloads
Download data is not yet available.
Citations
1. Neubauer S. The failing heart - an engine out of fuel. N Engl J Med 2007;356:1140-51. DOI: https://doi.org/10.1056/NEJMra063052
2. Doehner W, Frenneux M, Anker SD. Metabolic impairment in heart failure: the myocardial and systemic perspective. J Am Coll Cardiol 2014;64:1388-400. DOI: https://doi.org/10.1016/j.jacc.2014.04.083
3. Suskin N, McKelvie RS, Burns RJ, et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 2000;21:1368-75. DOI: https://doi.org/10.1053/euhj.1999.2043
4. AlZadjali MA, Godfrey V, Khan F, et al. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol 2009;53:747-53. DOI: https://doi.org/10.1016/j.jacc.2008.08.081
5. Dei Cas A, Khan SS, Butler J, et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail 2015;3:136-45. DOI: https://doi.org/10.1016/j.jchf.2014.08.004
6. Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patient with stable chronic heart failure. J Am Coll Cardiol 2005;46:1019-26. DOI: https://doi.org/10.1016/j.jacc.2005.02.093
7. Doehner W. A direct link between haemodynamic failure and inflammatory activation in heart failure: the simplified approach to heart failure and to creation of life. Eur Heart J 2014;35:413-5. DOI: https://doi.org/10.1093/eurheartj/eht562
8. Wong AKF, Struthers AD, Choy AMJ, Lang CC. Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones. Heart Fail Clin 2012;8:539-50. DOI: https://doi.org/10.1016/j.hfc.2012.06.002
9. Papanas N, Maltezos E, Mikhailidis DP. Metformin and heart failure: never say never again. Expert Opin Pharmacother 2012;13:1-8. DOI: https://doi.org/10.1517/14656566.2012.638283
10. Larsen AH, Wiggers H, Dollerup OL, et al. Metformin lowers body weight but fails to increase insulin sensitivity in chronic heart failure patients without diabetes: a randomized, double-blind, placebo-controlled study. Cardiovasc Drugs Ther 2021;35:491-503. DOI: https://doi.org/10.1007/s10557-020-07050-5
11. Wong AK, Symon R, AlZadjali MA, et al. The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail 2012;14:1303-10. DOI: https://doi.org/10.1093/eurjhf/hfs106
12. Larsen AH, Jessen N, Nørrelund H, et al. A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes. Eur J Heart Fail 2020;22:1628-37. DOI: https://doi.org/10.1002/ejhf.1656
13. Dludla PV, Nyambuya TM, Johnson R, et al. Metformin and heart failure-related outcomes in patients with or without diabetes: a systematic review of randomized controlled trials. Heart Fail Rev 2021;26:1437-45. DOI: https://doi.org/10.1007/s10741-020-09942-y
14. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413-24. DOI: https://doi.org/10.1056/NEJMoa2022190
15. Packer M. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism. Nat Rev Cardiol 2023;20:443-62. DOI: https://doi.org/10.1038/s41569-022-00824-4
16. Kern M, Klöting N, Mark M, et al. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism 2016;65:114-23. DOI: https://doi.org/10.1016/j.metabol.2015.10.010
17. Hattori Y. Insulin resistance and heart failure during treatment with sodium glucose cotransporter 2 inhibitors: proposed role of ketone utilization. Heart Fail Rev 2020 25:403-8. DOI: https://doi.org/10.1007/s10741-020-09921-3
18. Goedeke L, Ma Y, Gaspar RC, et al. SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts. J Clin Invest 2024;134:e176708. DOI: https://doi.org/10.1172/JCI176708
19. Schulz-Menger J, Bluemke DA, Bremerich J, et al. Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update: Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post-Processing. J Cardiovasc Magn Reson 2020;22:19. DOI: https://doi.org/10.1186/s12968-020-00610-6
20. Pouleur AC, Dang PL, Knappe D, et al. Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: the MADIT-CRT trial. Eur Heart J 2011;32:1720-9. DOI: https://doi.org/10.1093/eurheartj/ehr185
21. Dang PL. Therapeutic and clinical relevance of left ventricular longitudinal strain analyzed by speckle-tracking echocardiography. Proceedings Annual Congress of the German Cardiac Society; 2016. P. 437-157.
22. Rosano GMC, Coats AJS. Modulation of cardiac metabolism in heart failure. Global Cardiology 2024;3:30. DOI: https://doi.org/10.4081/cardio.2024.30
23. Snoer M, Monk-Hansen T, Olsen RH, et al. Insulin resistance and exercise tolerance in heart failure patients: linkage to coronary flow reserve and peripheral vascular function. Cardiovasc Diabeto. 2012;11:97. DOI: https://doi.org/10.1186/1475-2840-11-97
24. Scherbakov N, Bauer M, Sandek A, et al. Insulin resistance in heart failure: differences between patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 2015;17:1015-21. DOI: https://doi.org/10.1002/ejhf.317
25. Riehle C, Abel ED. Insulin signaling and heart failure. Circ Res 2016;118:1151-69. DOI: https://doi.org/10.1161/CIRCRESAHA.116.306206
26. Chang HR, Hsieh JC, Hsu BG, et al. Inverse association of N-terminal pro-B-type natriuretic peptide with metabolic syndrome in patients with congestive heart failure. PLoS One 2013;8:e79096. DOI: https://doi.org/10.1371/journal.pone.0079096
27. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008. DOI: https://doi.org/10.1056/NEJMoa1911303
28. Lascu A, Ionică LN, Merce AP, et al. Metformin acutely mitigates oxidative stress in human atrial tissue: a pilot study in overweight non-diabetic cardiac patients. Life (Basel) 2022;12:2058. DOI: https://doi.org/10.3390/life12122058
29. Bolívar S, Noriega L, Ortega S, et al. Novel targets of metformin in cardioprotection: beyond the effects mediated by AMPK. Curr Pharm Des 2021;27:80-90. DOI: https://doi.org/10.2174/1381612826666200509232610
30. Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111:583-90. DOI: https://doi.org/10.1161/01.CIR.0000154542.13412.B1
31. Eurich DT et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013;6:395-402. DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.112.000162
32. Aguilar D, Chan W, Bozkurt B, et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 2011;4:53-8. DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.110.952556
33. Rachmani R, Slavachevski I, Levi Z, et al. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med 2002;13:428. DOI: https://doi.org/10.1016/S0953-6205(02)00131-0
34. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;2010:CD002967. DOI: https://doi.org/10.1002/14651858.CD002967.pub3
35. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131. DOI: https://doi.org/10.1002/ejhf.2333
36. Usman MS, Hamid A, Qazi SU, et al. The effect of SGLT2 inhibitors on health status in patients with heart failure: a systematic review and meta¬analysis. Global Cardiology 2024;2:35. DOI: https://doi.org/10.4081/cardio.2024.35
37. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451-61. DOI: https://doi.org/10.1056/NEJMoa2107038
38. Siddiqi TJ, Butler J, Coats AJS , et al. SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials. Global Cardiology 2023;1:2. DOI: https://doi.org/10.4081/cardio.2023.2
How to Cite
1.
Doehner W, Friede T, Edelmann F, Landmesser U, Winkler S, Pieske B, et al. Effect of metformin and empagliflozin on myocardial function in insulin-resistant patients with heart failure: rationale and design of the METRIS-HF-DZHK18 Trial. Global Cardiol [Internet]. 2025 Dec. 31 [cited 2026 Jan. 18];3(4). Available from: https://www.globalcardiology.info/site/article/view/89
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
